Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.44 |
| ▸ | CMA1 | P23946 | 1/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17316399 | 0.84 | HDAC1 (0.50) | KMT2AMEN1MAPTSMN1; SMN2LMNA | |
| SCHEMBL17316285 | 0.84 | LMNA (0.49) | KMT2AMEN1MAPTSMN1; SMN2LMNA | |
| SCHEMBL1857009 | 0.84 | LMNA (0.52) | KMT2AMEN1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL17316638 | 0.82 | LMNA (0.42) | KMT2AMEN1LMNAPKM | |
| SCHEMBL17316305 | 0.82 | CACNA1H (0.47) | KMT2AMEN1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL17316771 | 0.82 | CACNA1G (0.50) | KMT2AMEN1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL1865930 | 0.82 | LMNA (0.47) | KMT2AMEN1CACNA1GCACNA1HCACNA1I | |
| SCHEMBL17316432 | 0.82 | PKM (0.52) | KMT2AMEN1LMNAPKM | |
| SCHEMBL185087 | 0.81 | LMNA (0.53) | KMT2AMEN1SMN1; SMN2LMNARAB9A | |
| SCHEMBL17316797 | 0.81 | MAPT (0.41) | KMT2AMEN1MAPTLMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414429-B | Pyrazole compounds and their use as T-type calcium channel blockers | 爱杜西亚药品有限公司 | 2020-01-03 | — | — | CN | disclosed |
| CN-105669558-B | Benzyl -1H- pyrazoles, benzyl -1H- azole derivatives and its preparation method and application | 四川大学 | 2019-01-22 | — | — | CN | disclosed |
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-09-04 | — | — | US | disclosed |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-19 | — | — | US | disclosed |
| US-9932314-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-04-03 | — | — | US | disclosed |
| EP-3152199-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | Actelion Pharmaceuticals Ltd. (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-04-06 | — | — | US | disclosed |
| CN-106414429-A | Pyrazole compounds and their use as T-type calcium channel blockers | 埃科特莱茵药品有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-106146400-A | Benzyl-1H-pyrazoles, benzyl-1H-azole derivatives and its production and use | 四川大学 | 2016-11-23 | — | — | CN | disclosed |
| WO-2015186056-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-12-10 | — | — | WO | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065929-B2 | Pyrazole compounds and their use as T-type calcium channel blockers | CACNA1E, CACNA1I, CACNA1G | KMT2A 4227/4885MEN1 711/4885CACNA1G 3/4885 |
| US-20170096399-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | KMT2A 4227/4885MEN1 711/4885CACNA1G 3/4885 |
| US-20180105496-A1 | PYRAZOLE COMPOUNDS AND THEIR USE AS T-TYPE CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1I, CACNA1G | KMT2A 4227/4885MEN1 711/4885CACNA1G 3/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | KMT2A 4296/4885MEN1 4026/4885CACNA1G 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.